Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of Xolair in chronic idiopathic urticaria refractory to H1 antihistamines
2009-009498-87Phase 2Completed
- Sponsor
- Genentech
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omalizumab in chronic idiopathic urticaria (CIU) and chronic urticaria (CU) (4 arms), sponsored by Genentech. Primary endpoint: Primary efficacy endpoint. Started Mar 2009; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)chronic urticaria (CU)
Beyond the preview
Go deeper on 2009-009498-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009498-87.